Active, not recruiting
Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL
NCT07480863
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, beijing, Beijing, China